Skip to main content

Table 2 Palliative chemotherapies and therapeutic regimens used in the study population

From: Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung

Characteristics

All

(n = 79)

Chemotherapy line, n (%)

 First line

19 (24.1)

 Second line

24 (30.4)

 Third line

21 (26.6)

 Forth line

15 (19.0)

Chemotherapy cycle, median [interquartile range]

 First line

4.0 [2.0–10.0]

 Second line

4.0 [2.0–8.0]

 Third line

4.0 [2.0–7.5]

Conventional chemotherapy regimen, n (%)

 Platinum & Pemetrexed

40 (50.6)

 Platinum & Gemcitabine

30 (38.0)

 Platinum & Taxane

5 (6.3)

 Pemetrexed

27 (34.2)

 Gencitabine

9 (11.4)

 Taxane

14 (17.7)

 Navelbine

12 (15.2)

 Othersa

7 (8.9)

Targeted therapy, n (%)

13 (16.5)

 EGFR-TKI

8 (10.1)

 ALK-TKI

4 (5.1)

 Other TKIb

1 (1.3)

Immunotherapy, n (%)

18 (22.8)

 Nivolumab

7 (8.9)

 Pembrolizumab

3 (3.8)

 Atezolizumab

4 (5.1)

 Duvalumab

2 (2.5)

 Avelumab

1 (1.3)

 Other immunotherapiesc

3 (3.8)

  1. Results are reported as a number (%) or median [interquartile range]. EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, ALK anaplastic lymphoma receptor tyrosine kinase. aOthers comprised 3 irinotecan with platinum, 1 navelbine with platinum, 1 gemcitabine with navelbine, and 2 carboplatin treatment cases. bOther TKI was entrectinib. cOther immunotherapies were PDR001, MK1308, and MEDI5752